科研之友
微信
新浪微博
Facebook
分享链接
摘要
Cabozantinib (XL184) is a novel small molecule inhibitor of receptor tyrosine kinases (RTKs) targeted at mesenchymal-epithelial transition factor (MET). In order to study the pharmacokinetics and tissue distribution in rat, a specific ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method was developed with midazolam as internal standard. The calibration curves in plasma and tissues were linear in the range of 5-5000 ng/mL (r(2) > 0.99). The recoveries were better than 80.4% and matrix effects ranged from 96.9% to 105.1%. Then, the developed UPLC-MS/MS method was applied to determine the concentration of XL184 in blood and tissues. The pharmacokinetics of four different dosages (iv 5, 10 mg/kg and ig 15, 30 mg/kg) revealed that XL184 was eliminated slowly, the t(1/2) was longer than 10 h and the absolute bioavailability was 25.6 +/- 8.3%. The concentration distribution of XL184 in tissues was liver > lung > kidney > spleen > heart. Based on the concentration-time of XL184 in tissues, a BP-ANN distribution model was developed with good performance, and can be used to predict the concentration of XL184 in tissues.
